Syrris Celebrates its Most Successful Year to Date
News Feb 26, 2014
Syrris continues to lead the way with its batch reactor products and flow chemistry systems, increasing profits by over 50 % year-on-year.
This includes the top 20 pharmaceutical companies, leading universities and government institutes, plus companies working in fields such as food, flavor and fragrance, petrochemicals, nanoparticles and fine chemical synthesis.
Highlights of 2013 included a global series of workshops - enabling chemists to discover the advantages of flow and automated process chemistry - and the launch of an exclusive Customer Club, offering members easy access to a wide variety of select benefits and additional information.
Syrris also committed to a three-year, multi-million pound research and development program, part funded by European Union and Technology Strategy Board grants which were awarded in recognition of the Company’s ability to develop innovative, user-friendly and commercially successful products for chemists and chemical engineers.
The program will allow existing award-winning products, including Asia and Atlas reactors, to be further enhanced, and novel batch and flow chemistry products to be developed.
CEO Mike Hawes commented: “This is a really exciting time in Syrris’ history. Our most successful year ever has established Syrris as the market leader in flow chemistry products. The launch of our research and development program will deliver further world-class products offering the greatest control and ultimate ease of use to our customers, enabling a broader array of chemistry on a wider scale than ever before.”
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
Synthesis Strategy Could Mean Wave of New Medicinal CompoundsNews
In pharmacology, not all molecular structures are created equal. Some frameworks are overrepresented in nature, making them especially attractive to scientists on the hunt for more effective drugs. One such structure, the carbocyclic 5-8-5 fused ring system, is notoriously difficult to produce using conventional laboratory methods. Now, an innovative synthetic technique could unlock these elusive structures.READ MORE